RAD51 and neoplasm: In addition, it significantly inhibits the expression of NF-κB signaling dependent proinflammatory genes IL-6 and IL-1B through RAD51, thus blocking the STING-associated anti-tumor immunity in stromal tumor-infiltrating lymphocytes (sTILs).